Protein degradation through covalent inhibitor-based PROTACs

Area of Science:

• Biochemistry
• Molecular Biology
• Medicinal Chemistry

Background:

• Proteolysis Targeting Chimeras (PROTACs) represent a significant advancement in targeted protein degradation.
• The development of PROTACs utilizing covalent inhibitors has been a subject of ongoing debate and research.
• Targeting specific kinases like Bruton's tyrosine kinase (BTK) and B-cell linker protein (BLK) is crucial in various therapeutic areas.

Purpose of the Study:

• To investigate the feasibility and efficacy of developing Proteolysis Targeting Chimeras (PROTACs) based on covalent inhibitors.
• To design and synthesize novel covalent inhibitor-based PROTACs.
• To demonstrate the capability of these novel PROTACs to degrade target kinases, specifically BTK and BLK.

Main Methods:

• Design and synthesis of chimeric molecules incorporating covalent warheads and E3 ligase ligands.
• In vitro and in cell-based assays to assess the degradation of target proteins (BTK and BLK).
• Biochemical and biophysical techniques to confirm target engagement and degradation mechanism.

Main Results:

• Successful development of chimeric degraders utilizing covalent inhibitors.
• Demonstrated degradation of BTK and BLK kinases by the novel covalent inhibitor-based PROTACs.
• Confirmation of the viability and effectiveness of this PROTAC strategy.

Conclusions:

• Covalent inhibitor-based Proteolysis Targeting Chimeras (PROTACs) are a viable and effective therapeutic modality.
• This approach expands the toolbox for targeted protein degradation, offering new avenues for drug discovery.
• The successful degradation of BTK and BLK kinases highlights the potential of this technology in treating relevant diseases.